Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J ECT ; 26(4): 282-8, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20357671

RESUMO

OBJECTIVES: The effectiveness of electroconvulsive therapy (ECT) in pharmacotherapy-resistant major depressive disorder and schizophrenia has been shown for all age groups. Nevertheless, age-specific adverse effects such as greater cognitive impairment and higher somatic risks due to medical comorbidities and concomitant medication may be limiting factors in geriatric patients. METHODS: We retrospectively evaluated 4457 treatments in 380 patients to investigate the influence of age on ECT outcome, safety, and adverse effects. Clinical variables, treatment modalities, and neurophysiological parameters were analyzed. For modeling the influence of age on these variables of interest, linear and logistic regression models were performed. RESULTS: The mean (SD) age of our patients was 51.2 (15) years; 30% were older than 60 years. Diagnoses were major depressive disorder in 74.4% and schizophrenia in 25.6%. We found a considerable clinical improvement in all age groups. A higher severity of disease at admission corresponded to a better clinical response. Analyzing treatment modalities of elderly patients older than 60 years, no significant differences in need and number of concomitant psychotropic medications were seen, but significant differences were seen in medical co-medication. Ictal and postictal neurophysiological parameters were only in part predictive for clinical outcome, but age had a significant influence on most of them. Transient cardiovascular adverse effects and cognitive disturbances were more frequent in the elderly. In most cases, there was no need for any specific treatment. CONCLUSIONS: Our data confirm previous studies indicating the good effectiveness of ECT irrespective of age. We also found an excellent tolerability profile in the elderly in our patient sample. There was no mortality, and only transient and no life-threatening adverse events occurred.


Assuntos
Envelhecimento/fisiologia , Eletroconvulsoterapia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Anestesia , Eletroconvulsoterapia/efeitos adversos , Eletroencefalografia , Eletromiografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Estatísticos , Estudos Retrospectivos , Convulsões/fisiopatologia , Resultado do Tratamento , Adulto Jovem
2.
World J Biol Psychiatry ; 11(2 Pt 2): 516-8, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20218806

RESUMO

Zolpidem, a non-benzodiazepine hypnotic, acts selectively via the alpha(1)-subunit of GABA(A) receptors at therapeutic doses. It is therefore thought to lack both benzodiazepine properties such as anxiolysis, anticonvulsion, muscle relaxation, and side effects such as dependency. We report a case of severe dependency of zolpidem taken because of percieved myorelaxation in a patient with multiple sclerosis and paraspasticity. The observations in the patient described here suggest that zolpidem looses alpha1-receptor selectivity at higher doses, thereby leading to the same risks and benefits such as benzodiazepines. This should be taken into account by doctors when prescribing higher doses. Zolpidem may improve symptoms of spasticity in high doses via affection of GABA alpha2-receptor and alpha3-receptor subunits.


Assuntos
Agonistas GABAérgicos/uso terapêutico , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Piridinas/uso terapêutico , Transtornos Relacionados ao Uso de Substâncias/fisiopatologia , Feminino , Humanos , Pessoa de Meia-Idade , Esclerose Múltipla Recidivante-Remitente/fisiopatologia , Espasticidade Muscular/tratamento farmacológico , Espasticidade Muscular/fisiopatologia , Transtornos Relacionados ao Uso de Substâncias/psicologia , Zolpidem
3.
World J Biol Psychiatry ; 11(2 Pt 2): 447-56, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19462341

RESUMO

BACKGROUND: Electroconvulsive therapy (ECT) is still considered the most effective biological treatment strategy in psychiatric disorders. However, the clinical efficacy of ECT may be affected by stimulus variables and the concomitant use of psychopharmacological medication. Furthermore, most anaesthetics have anticonvulsant properties and therefore might additionally influence the efficacy of ECT. METHOD: In order to explore whether different anaesthetics might alter the effectiveness or safety of ECT we retrospectively analyzed 5482 ECT treatments in 455 patients. Anaesthetics were chosen according to clinical reasons and comprised thiopental, methohexital, propofol and etomidate. RESULTS: Seizure duration was significantly affected by the anaesthetic medication with longest seizure activity during thiopental anaesthesia. In addition, postictal suppression, a further prospective parameter of ECT effectiveness, was significantly higher during propofol and thiopental anaesthesia. The clinical effectiveness was significantly better during propofol and thiopental anaesthesia. In contrast, the overall safety did not differ between the anaesthetic groups. CONCLUSION: Our study supports the hypothesis that inducting anaesthetic agents have a different impact on seizure duration, ictal and postictal electrophysiological indices and clinical efficacy of ECT. Compared to thiopental, which has been established as a standard anaesthetic during ECT, also the modern anaesthetic propofol is a suitable inducting agent.


Assuntos
Anestésicos Intravenosos , Eletroconvulsoterapia/métodos , Idoso , Anestesia Intravenosa , Anestésicos Intravenosos/farmacologia , Anestésicos Intravenosos/uso terapêutico , Eletroconvulsoterapia/efeitos adversos , Eletroencefalografia/efeitos dos fármacos , Eletromiografia/efeitos dos fármacos , Etomidato/farmacologia , Etomidato/uso terapêutico , Feminino , Humanos , Masculino , Metoexital/farmacologia , Metoexital/uso terapêutico , Pessoa de Meia-Idade , Propofol/farmacologia , Propofol/uso terapêutico , Estudos Retrospectivos , Convulsões/fisiopatologia , Tiopental/farmacologia , Tiopental/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...